This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Illumina-Grail deal reveals rift between EU competition authorities over M&A powers

By Nicholas Hirst and Natalie McNelis ( April 20, 2021, 12:40 GMT | Comment) -- Illumina's $7 billion bid for Grail has lifted the lid on divergences between national antitrust regulators and the bloc's merger watchdog. Several EU competition authorities have broken ranks with the European Commission's policy move to assert jurisdiction over "killer acquisitions." They say they can't refer deals to Brussels if they don't have jurisdiction to review them themselves, contradicting a key tenet of the EU regulator's new policy.Biotech company Illumina's planned acquisition of cancer testing start-up Grail can be referred for EU merger review even if national competition authorities don't have jurisdiction to look at the deal themselves....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login